ROCTAVIAN

What Is ROCTAVIAN and What Is It Used For?

Quick Answer: ROCTAVIAN is a gene therapy medicine containing valoctocogene roxaparvovec. It is used to treat severe hemophilia A in adults who do not have inhibitors against factor VIII and who do not have antibodies against the AAV5 viral vector. It is given as a single intravenous infusion.

Hemophilia A is a hereditary bleeding disorder caused by mutations in the gene responsible for producing factor VIII, a critical protein in the blood clotting cascade. People with severe hemophilia A produce little to no factor VIII, leaving them vulnerable to spontaneous internal and external bleeding episodes that can be life-threatening. Traditionally, treatment has involved frequent intravenous infusions of replacement factor VIII protein, often several times per week throughout the patient's lifetime.

ROCTAVIAN represents a paradigm shift in hemophilia A treatment. Rather than replacing the missing protein externally, it uses gene therapy technology to deliver a functional copy of the factor VIII gene directly into the patient's liver cells. The therapy is based on an adeno-associated virus serotype 5 (AAV5) vector — a modified virus that cannot cause disease in humans and cannot replicate inside the body. This viral vector serves as a delivery vehicle, carrying the corrective gene into hepatocytes (liver cells), where it instructs those cells to begin manufacturing their own factor VIII protein.

Once the liver cells take up the gene and begin producing factor VIII, the patient's blood gains improved clotting ability, which can reduce or potentially eliminate the need for ongoing factor VIII replacement therapy. The treatment is given as a single intravenous infusion, typically taking several hours to administer, and is designed to provide a lasting therapeutic effect from a single treatment session.

ROCTAVIAN received conditional marketing authorization from the European Medicines Agency (EMA) in 2022, and the FDA approved it for use in the United States in 2023. As a conditionally approved treatment, additional data on its long-term efficacy and safety continue to be collected. Clinical trials have shown that some patients maintained meaningful factor VIII production for up to 5 years, though the ultimate duration of the treatment effect remains under investigation.

How Does ROCTAVIAN Work?

The mechanism of action of ROCTAVIAN relies on adeno-associated virus (AAV) vector technology, one of the most advanced platforms in modern gene therapy. The AAV5 vector used in ROCTAVIAN has been engineered to be non-pathogenic, meaning it cannot cause infection or illness. Its outer protein shell (capsid) naturally has an affinity for liver cells, making it an ideal vehicle for hepatocyte-targeted gene delivery.

After intravenous infusion, the AAV5 vector particles circulate through the bloodstream and are taken up by liver cells. Once inside the hepatocyte, the vector releases its genetic payload — a functional human factor VIII gene (also known as the B-domain deleted factor VIII transgene, or BDD-FVIII). This transgene then persists in the nucleus of the liver cell, primarily in an extrachromosomal (episomal) form, where it directs the cell's protein-making machinery to produce factor VIII protein. The newly synthesized factor VIII is then secreted into the bloodstream, where it participates in the normal coagulation cascade.

It is important to understand that while the majority of the transgene remains episomal, some integration into the host cell DNA can occur. This has implications for long-term safety monitoring, which is discussed in detail in the warnings section of this guide. The degree of factor VIII production varies among patients, and the reasons why some patients achieve higher or more sustained levels than others are still being studied.

What Should You Know Before Receiving ROCTAVIAN?

Quick Answer: Before receiving ROCTAVIAN, you must be tested for antibodies against the AAV5 vector and factor VIII inhibitors. You must have adequate liver health and no active infections. You may need corticosteroid treatment for two months or longer after the infusion.

Contraindications

ROCTAVIAN must not be given in the following circumstances:

• Allergy: If you are allergic to valoctocogene roxaparvovec or any of the other ingredients in the medicine (disodium phosphate dodecahydrate, mannitol, poloxamer 188, sodium chloride, sodium dihydrogen phosphate dihydrate, and water for injections).
• Active infection: If you have an acute infection or a chronic infection that is not adequately controlled with treatment, as this may impair the body's initial response to ROCTAVIAN.
• Significant liver disease: If you have significant liver fibrosis or cirrhosis (scarring of the liver), as this can prevent ROCTAVIAN from working effectively.
• AAV5 antibodies: If you have pre-existing antibodies against the AAV5 virus used to manufacture this medicine. Your doctor will test you for these antibodies before treatment.

Warnings and Precautions

Corticosteroid therapy: After receiving ROCTAVIAN, you may need to take corticosteroids for an extended period (typically two months or longer) to manage immune-mediated liver inflammation that manifests as elevated liver enzymes in blood tests. Corticosteroids can cause their own side effects, including weight gain, mood changes, elevated blood sugar, and increased susceptibility to infections. Your doctor will guide you on tapering and discontinuing these medications appropriately. If you cannot tolerate corticosteroids, your doctor may recommend delaying or avoiding treatment with ROCTAVIAN.

Infusion-related reactions: Side effects related to the infusion can occur during or shortly after receiving ROCTAVIAN. These may include hives, itching, breathing difficulties, nausea, elevated or low blood pressure, rapid heart rate, and muscle or back pain. If you experience any of these symptoms, inform your healthcare team immediately. The infusion may be slowed, temporarily paused, or additional medications may be administered to manage symptoms.

Thromboembolic risk: Following treatment, factor VIII levels may rise above normal ranges in some patients. Elevated factor VIII levels, combined with individual risk factors, can increase the risk of unwanted blood clots (thrombosis) in veins or arteries. Discuss your personal risk factors for blood clots and cardiovascular disease with your doctor, and learn to recognize the symptoms of thromboembolism.

Immunocompromised patients: If your immune system is weakened or if you are taking immunosuppressive medications, speak with your doctor before starting ROCTAVIAN treatment. Additional monitoring may be required to ensure that treatment and any subsequent corticosteroid therapy can be safely managed.

Future gene therapy: After receiving ROCTAVIAN, your immune system will produce antibodies against the AAV5 vector capsid. It is currently unknown whether treatment can be repeated or whether future gene therapies using similar vectors will be possible. This is an important consideration to discuss with your healthcare team before committing to treatment.

Not all patients respond: It is important to understand that not all patients achieve a meaningful response to ROCTAVIAN. Your doctor cannot predict in advance whether you will respond to treatment. Patients who do not respond or who lose their response over time will still have been exposed to the potential long-term risks of gene therapy without receiving the therapeutic benefit.

Cancer risk: ROCTAVIAN can integrate into the DNA of liver cells and potentially into other cells in the body. This raises a theoretical risk that the therapy could contribute to cancer development, although no cases have been observed in clinical studies to date. After treatment, patients are recommended to enroll in a 15-year safety registry to monitor for any long-term adverse effects, including malignancy. Regular follow-up with your healthcare team is essential.

Pregnancy, Breastfeeding, and Fertility

ROCTAVIAN is not recommended for women who may become pregnant, as its effects on pregnancy and the unborn child are unknown. It is also unknown whether ROCTAVIAN is excreted in breast milk.

After a male patient receives ROCTAVIAN, he and any female partner must use effective contraception (such as a double-barrier method with condom and diaphragm) for at least 6 months to avoid the theoretical risk of the factor VIII transgene being transmitted to a child. Male patients must also not donate sperm during this 6-month period. Consult your doctor about suitable contraceptive methods.

Children and Adolescents

ROCTAVIAN is approved for use in adults only. It has not been studied in children or adolescents, and its safety and efficacy in pediatric populations have not been established.

Driving and Operating Machinery

Transient episodes of dizziness, near-fainting, fatigue, and headache have been reported after ROCTAVIAN infusion. If you experience these effects, exercise caution when driving or operating machinery until you are confident that ROCTAVIAN does not impair your ability to do so safely.

How Does ROCTAVIAN Interact with Other Drugs?

Quick Answer: ROCTAVIAN can interact with hepatotoxic medications, isotretinoin, certain HIV antiretrovirals, immunosuppressants, and some vaccines. Alcohol must be avoided for at least one year after treatment. Always inform your doctor about all medications you are taking.

Before and after receiving ROCTAVIAN, it is crucial to inform your healthcare provider about all medications you are currently taking, have recently taken, or plan to take. This includes prescription drugs, over-the-counter medications, herbal supplements, and vitamins. The first year after ROCTAVIAN infusion is particularly critical, as the liver needs to remain healthy to sustain factor VIII production while the transgene establishes itself.

Medications That May Affect Liver Function

Any medication that can cause liver damage (hepatotoxic drugs) should be avoided or used with extreme caution, especially during the first year after ROCTAVIAN treatment. Examples include certain antibiotics, antifungal agents, nonsteroidal anti-inflammatory drugs (NSAIDs) at high doses, and some herbal supplements such as kava and green tea extract in concentrated forms. Your doctor will review your complete medication list to identify potential liver-toxic agents.

Specific Drug Interactions

Alcohol

Alcohol consumption can impair the liver's ability to produce factor VIII after ROCTAVIAN treatment. You must avoid all alcohol for at least one year following treatment. After the first year, discuss with your doctor to determine what level of alcohol consumption, if any, may be acceptable based on your liver function test results and overall health status.

What Is the Correct Dosage of ROCTAVIAN?

Quick Answer: ROCTAVIAN is given as a single intravenous infusion. The dose is calculated based on body weight at 6 × 10¹³ vg/kg. The infusion is administered in a specialized healthcare facility and typically takes several hours.

Adults

Children

ROCTAVIAN is not approved for use in children or adolescents (under 18 years of age). Clinical studies in pediatric populations have not been conducted.

Elderly

No specific dose adjustments are made for elderly patients. The same weight-based dosing applies. However, elderly patients may have additional risk factors for thromboembolic events and may require closer monitoring of factor VIII levels and cardiovascular status after treatment.

Monitoring After Treatment

Regular blood tests are essential after receiving ROCTAVIAN to monitor your response to treatment. These tests will check:

• Factor VIII levels: To determine when your liver begins producing factor VIII and at what level, so you can work with your doctor to decide when to stop regular factor VIII replacement therapy.
• Liver function tests (ALT, AST): To detect immune-mediated liver inflammation that may require corticosteroid treatment.
• Factor VIII inhibitors: To check whether you develop neutralizing antibodies against factor VIII.
• Creatine phosphokinase (CPK): To monitor for muscle-related side effects.

During the first 26 weeks after treatment, blood tests are typically performed weekly. From weeks 26 to 52, testing frequency is reduced to every 2 to 4 weeks. After the first year, tests are taken less frequently as determined by your physician. It is critical to keep all scheduled monitoring appointments.

Missed Dose

ROCTAVIAN is administered as a single dose in a clinical setting, so a missed dose is not applicable in the traditional sense. If the infusion must be interrupted due to an adverse reaction, your healthcare team will determine the appropriate course of action, which may include resuming the infusion at a slower rate.

Overdose

Because ROCTAVIAN is administered in a hospital setting with the dose carefully calculated and verified by healthcare professionals, overdose is unlikely. If an excessive dose were administered, factor VIII levels could rise higher than necessary, potentially increasing the risk of thromboembolic events (blood clots). In such a case, the medical team would manage the situation with appropriate supportive care and close monitoring of coagulation parameters.

What Are the Side Effects of ROCTAVIAN?

Quick Answer: The most common side effects of ROCTAVIAN include elevated liver enzymes, nausea, headache, fatigue, and factor VIII levels above normal. Infusion-related reactions can also occur. Most side effects are manageable with medical supervision.

Like all medicines, ROCTAVIAN can cause side effects, although not everybody gets them. It is important to be aware of both the immediate side effects that may occur during or shortly after infusion, as well as delayed effects that may develop in the weeks and months following treatment. Your healthcare team will monitor you closely, especially during the first year, to detect and manage any adverse reactions promptly.

Infusion-Related Reactions

Infusion-related reactions may occur during or shortly after the ROCTAVIAN infusion. These are reported as common (affecting up to 1 in 10 people) and can include:

• Hives or other rashes, itching
• Breathing difficulties, sneezing, coughing, runny nose, watery eyes, itchy throat
• Nausea, diarrhea
• High or low blood pressure, rapid heartbeat, near-fainting
• Muscle pain, back pain
• Fever, chills, shivering

These symptoms can occur individually or in combination. If you experience any of these during your infusion, inform your healthcare team immediately. Depending on the severity, the infusion may be slowed, temporarily paused, or additional medications (such as antihistamines, corticosteroids, or intravenous fluids) may be administered. When resuming the infusion after an interruption, the rate will typically be restarted at 1 mL/min.

Liver Enzyme Elevation

Increases in liver enzymes (transaminases) are one of the most significant side effects of ROCTAVIAN and reflect an immune response by the body against the transduced liver cells. This elevation may occur at any point during the first year and can sometimes be accompanied by a decrease in factor VIII levels. When liver enzyme elevation is detected through routine blood monitoring, corticosteroid treatment is typically initiated to suppress the immune response and preserve the factor VIII-producing liver cells. It is crucial to attend all scheduled blood tests so that any liver enzyme changes can be detected and treated early.

How Should ROCTAVIAN Be Stored?

Quick Answer: ROCTAVIAN must be stored frozen at or below −60°C and is light-sensitive. Once thawed, it must be used within 10 hours at 25°C. It is handled exclusively by healthcare professionals in specialized facilities.

ROCTAVIAN is not stored at home. It is stored and handled exclusively by qualified healthcare professionals at specialized treatment facilities. However, understanding its storage requirements provides insight into the careful handling this gene therapy product demands:

• Frozen storage: ROCTAVIAN must be stored and transported in a deep-frozen state at or below −60°C (−76°F). The vials must be kept upright in their original packaging.
• Light sensitivity: The product is sensitive to light and must be protected from light at all times. It must not be exposed to ultraviolet disinfection lamps.
• Thawing: ROCTAVIAN is thawed at room temperature only, which takes approximately 2 hours. No other heating methods may be used.
• Post-thaw stability: Once thawed, the solution must be used within 10 hours at 25°C (77°F), including the time for preparation, filling syringes, and the infusion itself.
• Refrigerated storage: If needed, an intact (unopened) vial that has been thawed may be stored in a refrigerator (2°C–8°C / 36°F–46°F) for up to 3 days, upright and protected from light.
• Visual inspection: The thawed solution should be clear and colorless to pale yellow. Do not use if the solution is cloudy, discolored, or contains visible particles.
• Single use: Each vial is for single use only. Any unused product must be disposed of according to local regulations for pharmaceutical waste containing genetically modified organisms.

Keep this medicine out of the sight and reach of children. Do not use this medicine after the expiry date stated on the carton and vial label after "EXP." The expiry date refers to the last day of that month.

What Does ROCTAVIAN Contain?

Quick Answer: ROCTAVIAN contains the active substance valoctocogene roxaparvovec (an AAV5 vector carrying the factor VIII gene) and several inactive ingredients including sodium salts, mannitol, and poloxamer 188. Each vial contains 8 mL of solution.

Active Ingredient

The active substance is valoctocogene roxaparvovec, a genetically modified adeno-associated virus serotype 5 (AAV5) vector carrying a B-domain deleted human coagulation factor VIII transgene. Each milliliter of solution contains 2 × 10¹³ vector genomes (vg).

Inactive Ingredients (Excipients)

• Disodium phosphate dodecahydrate (E339)
• Mannitol (E421)
• Poloxamer 188
• Sodium chloride
• Sodium dihydrogen phosphate dihydrate (E339)
• Water for injections

Packaging

ROCTAVIAN is supplied as a single 8 mL vial of clear, colorless to pale yellow solution for infusion. This medicine contains genetically modified organisms (GMOs). Personal protective equipment (including a gown, safety goggles, mask, and gloves) must be worn by healthcare staff when handling the solution and any materials that have come into contact with it.

Marketing Authorization Holder: BioMarin International Ltd., Shanbally, Ringaskiddy, County Cork, P43 R298, Ireland.

References

1. European Medicines Agency (EMA). ROCTAVIAN Summary of Product Characteristics. Last updated 2023. Available from: EMA EPAR – ROCTAVIAN.
2. Mahlangu J, et al. Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A. N Engl J Med. 2023;388(8):694–705. doi:10.1056/NEJMoa2211075.
3. Ozelo MC, et al. Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A. N Engl J Med. 2022;386(11):1013–1025. doi:10.1056/NEJMoa2113708.
4. World Federation of Hemophilia (WFH). Guidelines for the Management of Hemophilia, 3rd edition. 2020. Available from: WFH Guidelines.
5. U.S. Food and Drug Administration (FDA). FDA Approves First Gene Therapy for Adults with Severe Hemophilia A. FDA News Release, June 2023.
6. Pipe SW, et al. Gene Therapy with Etranacogene Dezaparvovec for Hemophilia B – Context for AAV Gene Therapy Approaches. N Engl J Med. 2023;388(8):706–718.
7. George LA. Hemophilia Gene Therapy Comes of Age. Hematology Am Soc Hematol Educ Program. 2023;2023(1):587–594.
8. Srivastava A, et al. WFH Guidelines for the Management of Hemophilia, 3rd edition. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046.

Editorial Team

This article has been researched, written, and reviewed by the iMedic Medical Editorial Team, which includes board-certified specialists in hematology, gene therapy, and internal medicine. All content follows the GRADE evidence framework and adheres to international guidelines from the EMA, FDA, WFH, and WHO.

Evidence Level: 1A – Based on systematic reviews, randomized controlled trials, and international regulatory assessments (EMA, FDA). All medical claims are supported by peer-reviewed literature and regulatory documentation.

Conflict of Interest: The iMedic editorial team has no financial relationships with pharmaceutical companies. This content is produced independently with no commercial funding or sponsorship.